Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04815187 · ClinicalTrials.gov registry record · Phase 4
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
A Phase 4 study of Allergic Rhinitis and Vertigo, sponsored by House Ear Institute.
- Active
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT04815187: Active Phase 4 study of Allergic Rhinitis and Vertigo, sponsored by House Ear Institute.
NCT04815187 is a Phase 4 study of Allergic Rhinitis and Vertigo that is active but no longer recruiting, run by House Ear Institute. The registered enrollment target is 39 participants, below the 104-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (62% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04815187, a Phase 4 study of Allergic Rhinitis and Vertigo, is active but no longer recruiting, sponsored by House Ear Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.
Primary Outcome
Percentage of patients in each group with an AAO-HNS Vertigo Control Class A or B result (from daily diary count of number of attacks)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Montelukast
Study Locations (2)
California
- House Ear Clinic - Los Angeles
- House Institute Foundation - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2021-06-07 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 4 |
What the registry record for NCT04815187 still lists
NCT04815187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 104-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (62% lower).
The record links to 3 conditions, with Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04815187 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04815187 about?
NCT04815187 is a clinical study titled "Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease". The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.
What is the current status of trial NCT04815187?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2021-06-07. Estimated completion is 2025-12-31.
What conditions does trial NCT04815187 study?
This clinical trial studies the following conditions: Allergic Rhinitis, Vertigo, Meniere Disease.
What interventions are being tested in trial NCT04815187?
The interventions under investigation include: Placebo (DRUG), Montelukast (DRUG).
Who is sponsoring clinical trial NCT04815187?
This trial is sponsored by House Ear Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04815187 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04815187's enrollment target sits among peer trials
39 16th of 23 higher than 8 of 23 other Allergic Rhinitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
COMPLETED · Phase 4
-
The Effect of Cetirizine on Bronchoconstriction
COMPLETED · Phase 4
-
Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
COMPLETED · Phase 4
-
Comparability and Standardization of Controlled Allergen Challenge Facilities
COMPLETED · Phase 4
-
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
COMPLETED · Phase 4
-
Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI